Home › Funds › Frazier Life Sciences Management, L.P. › XLO
Frazier Life Sciences Management, L.P. position in XLO
XILIO THERAPEUTICS INC · Health Care
Frazier Life Sciences Management, L.P. reported holding 422,505 shares of XLO (XILIO THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$4.0M, representing 0.09% of its reported portfolio and ranking #40 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed XLO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s XLO position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in XLO in Q4 2025 at 5,915,091 shares (US$3.8M). The position peaked in Q2 2026 at 422,505 shares, worth US$4.0M. Across 3 filings, Frazier Life Sciences Management, L.P. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 422,505 shares valued at US$4.0M. Notable position changes include a 93% trim in Q1 2026 (shares rose 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 5.92M | $3.79M | New |
| Q1 2026 | 422.50K | $3.55M | Reduce |
| Q2 2026 | 422.50K | $4.05M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XLO and 13F data
XLO (XILIO THERAPEUTICS INC) is a Health Care company. 24 other funds we track also report a position in XLO — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$6.4M), GILEAD SCIENCES, INC. (US$6.2M), Stonepine Capital Management, LLC (US$2.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XLO
- Bain Capital Life Sciences Investors, LLC 664.02K sh · $6.36M · Q2 2026
- GILEAD SCIENCES, INC. 650.39K sh · $6.23M · Q2 2026
- Stonepine Capital Management, LLC 225.99K sh · $2.17M · Q2 2026
- Sio Capital Management, LLC 152.46K sh · $1.46M · Q2 2026
- Merck & Co., Inc. 105.98K sh · $1.02M · Q2 2026
- AJU IB Investment Co., Ltd. 47.70K sh · $401.12K · Q1 2026
- Velan Capital Investment Management LP 14.29K sh · $136.85K · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held XLO?
Frazier Life Sciences Management, L.P. has disclosed XLO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Frazier Life Sciences Management, L.P.'s current position in XLO?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 422.50K shares of XLO (XILIO THERAPEUTICS INC), valued at $4.05M, representing 0.09% of its reported portfolio and ranking #40.
Has Frazier Life Sciences Management, L.P. been buying or selling XLO?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in XLO. The position peaked in Q2 2026 at 422.50K shares.
Which other funds hold XLO?
Other major institutional holders of XLO include Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., Stonepine Capital Management, LLC, among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.